TORONTO, Aug. 13, 2018 (GLOBE NEWSWIRE) — Fleurish Cannabis Inc. (“Fleurish”), an exclusively female-focused cannabis health and wellness company, is proud to announce the company is now officially licensed as a producer of cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations.
With this licence, Fleurish will begin the cultivation of cannabis strains focused on meeting women’s specific needs at their state-of-the-art facility in Kemptville, Ontario.
“Today represents a significant milestone for Fleurish,” said Renée Ellison, Founder, Fleurish. “With the receipt of our Production Licence from Health Canada, we can now move forward and prepare to provide a cannabis experience crafted uniquely for women.”
Fleurish will cultivate premium quality, craft cannabis in their Kemptville facility near Ottawa, Ontario. The 20,000 sq ft facility on 8 acres of land houses 15,000 square feet of grow space, along with laboratory space that will be the primary research and development location of the Fleurish. Once operations reach full capacity, the facility is anticipated to produce 1,400 kg of cannabis annually.
“We are excited to begin cultivation of our debut line of premium cannabis products for women which will include dried flower and pre-rolls,” said Mary Beth Williamson, Incoming Chief Marketing Officer, Fleurish. “We have conducted extensive consumer research with over 1,500 women across Canada. We’re incorporating our learning from these studies in the development of our products and communication. In May, we unveiled the brand’s visual identity that we developed in partnership with the female-founded creative agency, apt. 3304.”
About Fleurish Cannabis
With our exclusive focus on female cannabis consumers, Fleurish Cannabis is developing premium solutions with a single-minded purpose: to help women. Our team of expert growers located in our state-of-the-art indoor facility, near Ottawa, Ontario, are designing and developing products to give women a cannabis experience crafted around their unique concerns.